ADAP — Adaptimmune Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $365.30m
- $218.36m
- $60.28m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 89.5 | 368 | 370 | 205 | 147 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20.7 | 20.7 | 34 | 38.1 | 46.9 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 120 | 398 | 415 | 255 | 208 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 51.9 | 46.7 | 51.4 | 71.5 | 71.7 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 182 | 451 | 470 | 329 | 283 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 34.3 | 39.1 | 62.5 | 64.5 | 72.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 57.9 | 110 | 264 | 247 | 243 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 124 | 341 | 206 | 81.9 | 39.5 |
Total Liabilities & Shareholders' Equity | 182 | 451 | 470 | 329 | 283 |
Total Common Shares Outstanding |